BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 21481098)

  • 21. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
    Bab I; Zimmer A; Melamed E
    Ann Med; 2009; 41(8):560-7. PubMed ID: 19634029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and localization of cannabinoid receptors in human immature oocytes and unfertilized metaphase-II oocytes.
    Peralta L; Agirregoitia E; Mendoza R; Expósito A; Casis L; Matorras R; Agirregoitia N
    Reprod Biomed Online; 2011 Sep; 23(3):372-9. PubMed ID: 21778114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional neuroanatomy of the endocannabinoid system.
    Pazos MR; Núñez E; Benito C; Tolón RM; Romero J
    Pharmacol Biochem Behav; 2005 Jun; 81(2):239-47. PubMed ID: 15936805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
    Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: endocannabinoids and their receptors in the enteric nervous system.
    Duncan M; Davison JS; Sharkey KA
    Aliment Pharmacol Ther; 2005 Oct; 22(8):667-83. PubMed ID: 16197488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
    Petrosino S; Di Marzo V
    Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoids for the treatment of inflammation.
    Ashton JC
    Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the endocannabinoid system in Alzheimer's disease: new perspectives.
    Pazos MR; Núñez E; Benito C; Tolón RM; Romero J
    Life Sci; 2004 Sep; 75(16):1907-15. PubMed ID: 15306158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.
    McCarberg BH; Barkin RL
    Am J Ther; 2007; 14(5):475-83. PubMed ID: 17890938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid signalling in the enteric nervous system.
    Galligan JJ
    Neurogastroenterol Motil; 2009 Sep; 21(9):899-902. PubMed ID: 19689654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocannabinoid system: An overview of its potential in current medical practice.
    Mouslech Z; Valla V
    Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.
    Zogopoulos P; Vasileiou I; Patsouris E; Theocharis S
    J Appl Toxicol; 2013 Apr; 33(4):246-64. PubMed ID: 23296873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the CB1 receptor in the regulation of sleep.
    Murillo-Rodríguez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1420-7. PubMed ID: 18514375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.
    Fichna J; Sałaga M; Stuart J; Saur D; Sobczak M; Zatorski H; Timmermans JP; Bradshaw HB; Ahn K; Storr MA
    Neurogastroenterol Motil; 2014 Apr; 26(4):470-81. PubMed ID: 24460851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of the Endocannabinoid System in the Central Nervous System.
    Hu SS; Mackie K
    Handb Exp Pharmacol; 2015; 231():59-93. PubMed ID: 26408158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease.
    Cappellano G; Uberti F; Caimmi PP; Pietronave S; Mary DA; Dianzani C; Micalizzi E; Melensi M; Boldorini R; Nicosia G; Crosio E; Chiocchetti A; Aina F; Prat M; Dianzani U; Vacca G; Ariatti C; Grossini E
    Can J Cardiol; 2013 Apr; 29(4):499-509. PubMed ID: 22926037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.